$NEOT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Evofem Biosciences, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Evofem Biosciences, Inc.. Get notifications about new insider transactions in Evofem Biosciences, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10 2021 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Buy | P | 1.03 | 24,500 | 25,235 | 440,388 | 415.9 K to 440.4 K (+5.89 %) |
| May 13 2021 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 1.25 | 90,000 | 112,500 | 90,000 | |
| May 13 2021 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 1.25 | 90,000 | 112,500 | 90,000 | |
| May 13 2021 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Option Exercise | A | 1.25 | 90,000 | 112,500 | 90,000 | |
| Mar 09 2021 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Buy | P | 2.28 | 45,249 | 103,168 | 906,137 | 860.9 K to 906.1 K (+5.26 %) |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 3.25 | 700,000 | 2,275,000 | 700,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Grant | A | 0.00 | 500,000 | 0 | 860,888 | 360.9 K to 860.9 K (+138.55 %) |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 3.25 | 150,000 | 487,500 | 150,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 200,000 | 0 | 481,852 | 281.9 K to 481.9 K (+70.96 %) |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Option Exercise | A | 3.25 | 150,000 | 487,500 | 150,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Grant | A | 0.00 | 200,000 | 0 | 458,168 | 258.2 K to 458.2 K (+77.47 %) |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Option Exercise | A | 3.25 | 150,000 | 487,500 | 150,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Grant | A | 0.00 | 200,000 | 0 | 343,542 | 143.5 K to 343.5 K (+139.33 %) |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Option Exercise | A | 3.25 | 150,000 | 487,500 | 150,000 | |
| Feb 03 2021 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Grant | A | 0.00 | 200,000 | 0 | 315,451 | 115.5 K to 315.5 K (+173.23 %) |
| Nov 18 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Buy | P | 2.17 | 7,760 | 16,839 | 258,168 | 250.4 K to 258.2 K (+3.10 %) |
| Nov 18 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Buy | P | 2.20 | 9,090 | 19,998 | 143,542 | 134.5 K to 143.5 K (+6.76 %) |
| Sep 11 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 2.08 | 3,000 | 6,240 | 279,052 | 276.1 K to 279.1 K (+1.09 %) |
| Sep 11 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 2.71 | 1,000 | 2,710 | 276,052 | 275.1 K to 276.1 K (+0.36 %) |
| Sep 10 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Sell | S | 3.26 | 122,500 | 399,350 | 360,888 | 483.4 K to 360.9 K (-25.34 %) |
| Jul 17 2020 | NEOT | Evofem Biosciences ... | Link Fund Solutions Ltd | 10% Owner | Sell | S | 0.23 | 9,138,504 | 2,101,856 | 0 | 9.1 M to 0 (-100.00 %) |
| Jul 09 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.30 | 20,381 | 67,257 | 275,052 | 295.4 K to 275.1 K (-6.90 %) |
| Jun 17 2020 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Buy | P | 2.85 | 5,000 | 14,250 | 5,000 | 0 to 5 K |
| Jun 16 2020 | NEOT | Evofem Biosciences ... | Kamdar Kim P. | Director | Buy | P | 2.94 | 5,000 | 14,700 | 9,287 | 4.3 K to 9.3 K (+116.63 %) |
| Jun 15 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Buy | P | 3.14 | 8,500 | 26,690 | 250,408 | 241.9 K to 250.4 K (+3.51 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | ACACIA RESEARCH CORP | 10% Owner | Sell | S | 3.21 | 9,138,504 | 29,325,459 | 1,000 | 9.1 M to 1,000 (-99.99 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | ACACIA RESEARCH CORP | 10% Owner | Sell | S | 3.21 | 9,138,504 | 29,325,459 | 1,000 | 9.1 M to 1,000 (-99.99 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Buy | P | 3.50 | 857,143 | 3,000,001 | 13,226,532 | 12.4 M to 13.2 M (+6.93 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Sell | S | 5.98 | 65 | 389 | 12,369,389 | 12.4 M to 12.4 M (0.00 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Sell | S | 5.79 | 73,814 | 427,383 | 12,369,454 | 12.4 M to 12.4 M (-0.59 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Sell | S | 5.04 | 3,211 | 16,183 | 12,443,268 | 12.4 M to 12.4 M (-0.03 %) |
| Jun 09 2020 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Buy | J | 5.13 | 78,013 | 400,207 | 12,446,479 | 12.4 M to 12.4 M (+0.63 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 3.31 | 42,810 | 141,701 | 237,605 | 280.4 K to 237.6 K (-15.27 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 3.31 | 31,548 | 104,424 | 115,451 | 147 K to 115.5 K (-21.46 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 3.31 | 85,620 | 283,402 | 479,085 | 564.7 K to 479.1 K (-15.16 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.31 | 15,455 | 51,156 | 293,509 | 309 K to 293.5 K (-5.00 %) |
| Jun 08 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 3.31 | 31,590 | 104,563 | 134,452 | 166 K to 134.5 K (-19.03 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 4.99 | 84,525 | 421,780 | 564,705 | 649.2 K to 564.7 K (-13.02 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 4.99 | 39,487 | 197,040 | 166,042 | 205.5 K to 166 K (-19.21 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 4.99 | 39,435 | 196,781 | 146,999 | 186.4 K to 147 K (-21.15 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 19,474 | 97,175 | 308,964 | 328.4 K to 309 K (-5.93 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 4.99 | 42,262 | 210,887 | 280,415 | 322.7 K to 280.4 K (-13.10 %) |
| May 26 2020 | NEOT | Evofem Biosciences ... | PDL BIOPHARMA, INC. | 10% Owner | Sell | J | 0.00 | 13,333,334 | 0 | 0 | 13.3 M to 0 (-100.00 %) |
| May 13 2020 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | O'Brien Anthony Stephen | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | O'Brien Anthony Stephen | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Rarick Lisa Dale | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Rarick Lisa Dale | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Kamdar Kim P. | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 13 2020 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Option Exercise | A | 5.06 | 50,000 | 253,000 | 50,000 | |
| May 08 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.24 | 3,802 | 19,922 | 328,438 | 332.2 K to 328.4 K (-1.14 %) |
| May 08 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 5.24 | 7,792 | 40,830 | 186,434 | 194.2 K to 186.4 K (-4.01 %) |
| May 08 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 5.24 | 8,420 | 44,121 | 322,677 | 331.1 K to 322.7 K (-2.54 %) |
| May 08 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 5.24 | 16,905 | 88,582 | 649,230 | 666.1 K to 649.2 K (-2.54 %) |
| May 08 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 5.24 | 7,802 | 40,882 | 205,529 | 213.3 K to 205.5 K (-3.66 %) |
| May 01 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Sell | S | 4.75 | 1,000 | 4,750 | 194,226 | 195.2 K to 194.2 K (-0.51 %) |
| May 01 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Sell | S | 4.66 | 1,000 | 4,660 | 195,226 | 196.2 K to 195.2 K (-0.51 %) |
| Apr 01 2020 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 0.00 | 150,000 | 0 | 150,000 | |
| Apr 01 2020 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | M | 0.00 | 37,500 | 0 | 0 | |
| Apr 01 2020 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | M | 0.00 | 37,500 | 0 | 325,000 | 287.5 K to 325 K (+13.04 %) |
| Feb 26 2020 | NEOT | Evofem Biosciences ... | Rarick Lisa Dale | Director | Option Exercise | A | 5.85 | 75,000 | 438,750 | 75,000 | |
| Feb 21 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Sell | S | 7.00 | 1,000 | 7,000 | 196,226 | 197.2 K to 196.2 K (-0.51 %) |
| Feb 21 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Sell | S | 6.50 | 14,957 | 97,221 | 332,240 | 347.2 K to 332.2 K (-4.31 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Option Exercise | A | 4.87 | 100,000 | 487,000 | 100,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 347,197 | 197.2 K to 347.2 K (+76.07 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 5.21 | 899 | 4,684 | 197,197 | 196.3 K to 197.2 K (+0.46 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Option Exercise | A | 4.87 | 300,000 | 1,461,000 | 300,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Grant | A | 0.00 | 300,000 | 0 | 666,135 | 366.1 K to 666.1 K (+81.94 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Grant | A | 5.21 | 3,846 | 20,038 | 366,135 | 362.3 K to 366.1 K (+1.06 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Option Exercise | A | 4.87 | 100,000 | 487,000 | 100,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Grant | A | 0.00 | 150,000 | 0 | 213,331 | 63.3 K to 213.3 K (+236.85 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Option Exercise | A | 4.87 | 100,000 | 487,000 | 100,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Grant | A | 0.00 | 150,000 | 0 | 331,097 | 181.1 K to 331.1 K (+82.83 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Grant | A | 5.21 | 3,846 | 20,038 | 181,097 | 177.3 K to 181.1 K (+2.17 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Option Exercise | A | 4.87 | 100,000 | 487,000 | 100,000 | |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Grant | A | 0.00 | 150,000 | 0 | 197,226 | 47.2 K to 197.2 K (+317.62 %) |
| Feb 07 2020 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Grant | A | 5.21 | 3,688 | 19,214 | 47,226 | 43.5 K to 47.2 K (+8.47 %) |
| Jan 21 2020 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Sell | S | 6.50 | 1,578 | 10,257 | 196,298 | 197.9 K to 196.3 K (-0.80 %) |
| Jan 15 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Sell | S | 6.00 | 1,648 | 9,888 | 177,251 | 178.9 K to 177.3 K (-0.92 %) |
| Jan 15 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Sell | S | 6.00 | 3,295 | 19,770 | 362,289 | 365.6 K to 362.3 K (-0.90 %) |
| Jan 06 2020 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Sell | S | 6.05 | 6,705 | 40,565 | 365,584 | 372.3 K to 365.6 K (-1.80 %) |
| Jan 06 2020 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Sell | S | 6.05 | 3,352 | 20,280 | 178,899 | 182.3 K to 178.9 K (-1.84 %) |
| Dec 31 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | M | 0.00 | 37,500 | 0 | 37,500 | |
| Dec 31 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | M | 0.00 | 37,500 | 0 | 287,500 | 250 K to 287.5 K (+15.00 %) |
| Dec 04 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Sell | S | 7.35 | 1,000 | 7,350 | 43,538 | 44.5 K to 43.5 K (-2.25 %) |
| Dec 04 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Sell | S | 7.16 | 10,000 | 71,600 | 182,251 | 192.3 K to 182.3 K (-5.20 %) |
| Dec 04 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Sell | S | 7.30 | 20,000 | 146,000 | 372,289 | 392.3 K to 372.3 K (-5.10 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 6.22 | 22,387 | 139,247 | 392,289 | 414.7 K to 392.3 K (-5.40 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 6.22 | 9,277 | 57,703 | 197,876 | 207.2 K to 197.9 K (-4.48 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 6.22 | 7,747 | 48,186 | 63,331 | 71.1 K to 63.3 K (-10.90 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 6.22 | 5,187 | 32,263 | 44,538 | 49.7 K to 44.5 K (-10.43 %) |
| Nov 26 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 6.22 | 10,102 | 62,834 | 192,251 | 202.4 K to 192.3 K (-4.99 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.74 | 9,044 | 51,913 | 207,153 | 216.2 K to 207.2 K (-4.18 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 5.74 | 5,187 | 29,773 | 49,725 | 54.9 K to 49.7 K (-9.45 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Sell | S | 6.01 | 10,000 | 60,100 | 414,676 | 424.7 K to 414.7 K (-2.35 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 5.74 | 22,657 | 130,051 | 424,676 | 447.3 K to 424.7 K (-5.06 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Sell | S | 6.00 | 4,900 | 29,400 | 202,353 | 207.3 K to 202.4 K (-2.36 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Sell | S | 6.00 | 100 | 600 | 207,253 | 207.4 K to 207.3 K (-0.05 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 5.74 | 10,102 | 57,985 | 207,353 | 217.5 K to 207.4 K (-4.65 %) |
| Nov 21 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 5.74 | 7,747 | 44,468 | 71,078 | 78.8 K to 71.1 K (-9.83 %) |
| Oct 17 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 5.01 | 18,427 | 92,319 | 78,825 | 97.3 K to 78.8 K (-18.95 %) |
| Oct 01 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | M | 0.00 | 37,500 | 0 | 75,000 | |
| Oct 01 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | M | 0.00 | 37,500 | 0 | 250,000 | 212.5 K to 250 K (+17.65 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 5.13 | 4,923 | 25,255 | 447,333 | 452.3 K to 447.3 K (-1.09 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 5.13 | 962 | 4,935 | 216,197 | 217.2 K to 216.2 K (-0.44 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 5.13 | 864 | 4,432 | 54,912 | 55.8 K to 54.9 K (-1.55 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 5.13 | 1,296 | 6,648 | 97,252 | 98.5 K to 97.3 K (-1.32 %) |
| Aug 26 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 5.13 | 1,558 | 7,993 | 217,455 | 219 K to 217.5 K (-0.71 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 13,257 | 66,152 | 217,159 | 230.4 K to 217.2 K (-5.75 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 230,416 | 80.4 K to 230.4 K (+186.53 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 4.99 | 13,257 | 66,152 | 217,159 | 230.4 K to 217.2 K (-5.75 %) |
| Jul 10 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Grant | A | 0.00 | 150,000 | 0 | 230,416 | 80.4 K to 230.4 K (+186.53 %) |
| Jul 01 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | M | 0.00 | 37,500 | 0 | 112,500 | |
| Jul 01 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | M | 0.00 | 37,500 | 0 | 212,500 | 175 K to 212.5 K (+21.43 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 6.36 | 5,965 | 37,937 | 80,416 | 86.4 K to 80.4 K (-6.91 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 6.36 | 5,187 | 32,989 | 55,776 | 61 K to 55.8 K (-8.51 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 6.36 | 10,185 | 64,777 | 219,013 | 229.2 K to 219 K (-4.44 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 6.36 | 35,826 | 227,853 | 452,256 | 488.1 K to 452.3 K (-7.34 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 6.36 | 7,777 | 49,462 | 98,548 | 106.3 K to 98.5 K (-7.31 %) |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | J | 6.38 | 555,556 | 3,544,447 | 555,556 | |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | J | 5.20 | 212,765 | 1,106,378 | 555,556 | |
| Jun 12 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Buy | P | 4.50 | 2,222,222 | 9,999,999 | 11,812,910 | 9.6 M to 11.8 M (+23.17 %) |
| Jun 10 2019 | NEOT | Evofem Biosciences ... | PDL BIOPHARMA, INC. | 10% Owner | Option Exercise | A | 6.38 | 1,666,667 | 10,633,335 | 1,666,667 | |
| Jun 10 2019 | NEOT | Evofem Biosciences ... | PDL BIOPHARMA, INC. | 10% Owner | Buy | P | 4.50 | 6,666,667 | 30,000,002 | 13,333,334 | 6.7 M to 13.3 M (+100.00 %) |
| Jun 06 2019 | NEOT | Evofem Biosciences ... | Rutherford Colin | Director | Option Exercise | A | 6.05 | 50,000 | 302,500 | 50,000 | |
| Jun 06 2019 | NEOT | Evofem Biosciences ... | O'Brien Anthony Stephen | Director | Option Exercise | A | 6.05 | 50,000 | 302,500 | 50,000 | |
| Jun 06 2019 | NEOT | Evofem Biosciences ... | Hall William Walmsley | Director | Option Exercise | A | 6.05 | 50,000 | 302,500 | 50,000 | |
| Jun 06 2019 | NEOT | Evofem Biosciences ... | Greer Gillian | Director | Option Exercise | A | 6.05 | 50,000 | 302,500 | 50,000 | |
| May 23 2019 | NEOT | Evofem Biosciences ... | Kamdar Kim P. | Director | Buy | J | 0.00 | 4,287 | 0 | 4,287 | 0 to 4.3 K |
| May 23 2019 | NEOT | Evofem Biosciences ... | Kamdar Kim P. | Director | Sell | S | 5.07 | 655 | 3,321 | 0 | 655 to 0 (-100.00 %) |
| Apr 15 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | J | 6.38 | 555,556 | 3,544,447 | 2,777,778 | |
| Apr 15 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | J | 4.50 | 2,222,222 | 9,999,999 | 2,777,778 | |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | File Justin J. | Chief Financial Off ... | Payment of Exercise | F | 3.55 | 1,292 | 4,587 | 229,198 | 230.5 K to 229.2 K (-0.56 %) |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 3.55 | 1,298 | 4,608 | 106,325 | 107.6 K to 106.3 K (-1.21 %) |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Payment of Exercise | F | 3.55 | 1,022 | 3,628 | 60,963 | 62 K to 61 K (-1.65 %) |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Option Exercise | A | 0.00 | 150,000 | 0 | 150,000 | |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Payment of Exercise | F | 3.55 | 1,160 | 4,118 | 86,381 | 87.5 K to 86.4 K (-1.33 %) |
| Apr 03 2019 | NEOT | Evofem Biosciences ... | PELLETIER SAUNDRA L | Chief Executive Off ... | Payment of Exercise | F | 3.55 | 3,731 | 13,245 | 488,082 | 491.8 K to 488.1 K (-0.76 %) |
| Feb 12 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Option Exercise | P | 5.20 | 212,765 | 1,106,378 | 212,765 | |
| Feb 12 2019 | NEOT | Evofem Biosciences ... | Invesco Ltd. | 10% Owner | Buy | P | 2.64 | 425,531 | 1,123,402 | 9,590,688 | 9.2 M to 9.6 M (+4.64 %) |
| Nov 26 2018 | NEOT | Evofem Biosciences ... | Barrans Russell | Chief Commercial Of ... | Buy | P | 3.55 | 279 | 990 | 12,820 | 12.5 K to 12.8 K (+2.22 %) |
| Oct 17 2018 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Payment of Exercise | F | 3.78 | 17,377 | 65,685 | 57,623 | 75 K to 57.6 K (-23.17 %) |
| Aug 21 2018 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Buy | P | 2.27 | 500 | 1,135 | 75,000 | 74.5 K to 75 K (+0.67 %) |
| Aug 21 2018 | NEOT | Evofem Biosciences ... | Fitzpatrick Alexander A | General Counsel and ... | Buy | P | 2.20 | 4,500 | 9,900 | 74,500 | 70 K to 74.5 K (+6.43 %) |
| Aug 20 2018 | NEOT | Evofem Biosciences ... | Culwell Kelly | Chief Medical Offic ... | Buy | P | 2.24 | 3,000 | 6,720 | 11,985 | 9 K to 12 K (+33.39 %) |
| Aug 15 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | P | 2.33 | 68,929 | 160,605 | 175,000 | 106.1 K to 175 K (+64.98 %) |
| Aug 15 2018 | NEOT | Evofem Biosciences ... | Lynch Thomas G | Director | Buy | P | 2.10 | 31,071 | 65,249 | 106,071 | 75 K to 106.1 K (+41.43 %) |